{
 "id": "ankylosing-spondylitis",
 "name": "Ankylosing spondylitis",
 "aliases": [
  "Ankylosing spondylitis (AS)"
 ],
 "acronyms": [
  "AS"
 ],
 "bodySystem": "immune",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 1
 },
 "funds": [
  {
   "fund": "Ankylosing spondylitis (AS)",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 4400,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "ETANERCEPT",
   "pages": [
    {
     "brand": "Enbrel",
     "url": "https://omnirx.org/negotiated-drugs/enbrel"
    }
   ],
   "labelSentence": "Ankylosing Spondylitis (AS) ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22a002b40c-097d-47a5-957f-7a7b1807af7f%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Enbrel Support (via Amgen)",
     "url": "https://omnirx.org/assistance/enbrel-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "RA Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/rheumatoid-arthritis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Amgen Safety Net Foundation",
     "url": "https://www.amgensafetynetfoundation.com/eligibility.html",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Eligibility page medication selector (tile titles)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 2418.7,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "SECUKINUMAB",
   "pages": [
    {
     "brand": "Cosentyx",
     "url": "https://omnirx.org/negotiated-drugs/cosentyx"
    }
   ],
   "labelSentence": "... active ankylosing spondylitis (AS) in adults and pediatric patients 12 years of age and older.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2277c4b13e-7df3-42d4-81db-3d0cddb7f67a%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Cosentyx Connect (via Novartis)",
     "url": "https://omnirx.org/assistance/cosentyx-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-07"
    },
    {
     "name": "Novartis Patient Assistance Foundation (NPAF)",
     "url": "https://pap.novartis.com/medications-list/",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "NPAF medications list",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "TOFACITINIB",
   "pages": [
    {
     "brand": "Xeljanz",
     "url": "https://omnirx.org/negotiated-drugs/xeljanz"
    }
   ],
   "labelSentence": "Active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22253635c8-1ea7-41ba-b216-dea5e3305c47%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Pfizer RxPathways",
     "url": "https://omnirx.org/assistance/pfizer-rxpathways",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": "no new patients starting July 1, 2026",
     "listKind": "products remaining within Pfizer PAP as of January 1, 2026",
     "status": "limited",
     "statusRead": "2026-11-07"
    },
    {
     "name": "RA Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/rheumatoid-arthritis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Adalimumab",
   "pages": [
    {
     "brand": "Humira",
     "url": "https://omnirx.org/medicines/humira"
    }
   ],
   "labelSentence": "Ankylosing Spondylitis (AS) ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%222488b0bc-7b8f-4cc8-91ea-48e7ea5e8915%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Humira Complete (via myAbbVie Assist)",
     "url": "https://omnirx.org/assistance/humira-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "myAbbVie Assist",
     "url": "https://omnirx.org/assistance/abbvie-myabbvie-assist",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Available medicines (myAbbVie Assist)",
     "status": null,
     "statusRead": null
    },
    {
     "name": "RA Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/rheumatoid-arthritis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Golimumab",
   "pages": [
    {
     "brand": "Simponi",
     "url": "https://omnirx.org/medicines/simponi"
    }
   ],
   "labelSentence": "Adult patients with active Ankylosing Spondylitis (AS) ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%229e260a47-55af-4c92-8d88-a86ccc767fff%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Johnson & Johnson Patient Assistance Program",
     "url": "https://omnirx.org/assistance/johnson-and-johnson-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines in the Quick Reference Guide picker on the program page",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Ixekizumab",
   "pages": [
    {
     "brand": "Taltz",
     "url": "https://omnirx.org/medicines/taltz"
    }
   ],
   "labelSentence": "... adults with active ankylosing spondylitis.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22ac96658a-d7dc-4c7c-8928-2adcdf4318b2%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Lilly Cares",
     "url": "https://omnirx.org/assistance/lilly-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Available Medications: list of all products",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "CERTOLIZUMAB PEGOL",
   "pages": [
    {
     "brand": "Cimzia",
     "url": "https://omnirx.org/negotiated-drugs/cimzia"
    }
   ],
   "labelSentence": "Treatment of adults with active ankylosing spondylitis ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22b4c2c9dc-a0bb-4d64-a667-a67ebe88392d%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Corticotropin",
   "pages": [
    {
     "brand": "Acthar",
     "url": "https://omnirx.org/medicines/acthar"
    }
   ],
   "labelSentence": "Ankylosing spondylitis;",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22110a17aa-6ed9-4458-8e67-1a742ce448e4%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Infliximab",
   "pages": [
    {
     "brand": "Remicade",
     "url": "https://omnirx.org/medicines/remicade"
    }
   ],
   "labelSentence": "Ankylosing Spondylitis : reducing signs and symptoms in adult patients with active disease.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22a0a046c1-056d-45a9-bfd9-13b47c24f257%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}